Admetric Biochem

Admetric Biochem, Inc. was a biotechnology company based in Massachusetts that specialized in developing advanced analytical platforms for drug discovery. The company's core technology centered on Immobilized Artificial Membrane (IAM) chromatography and 'fingerprinting' techniques designed to predict the ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties of small molecule drug candidates. By providing high-throughput screening tools, Admetric Biochem aimed to streamline the identification of viable leads and optimize pharmacokinetic profiles early in the development process. Despite its innovative contributions to the field of analytical biochemistry and drug target classification, the company ceased operations following a Chapter 7 bankruptcy filing in 2002.